TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, built on the premise of learning from patients who are winning their fight against cancer to treat those who are not. Its core asset is the ImmunoBank, a repository of therapeutic TCRs, all derived from the company's proprietary platform technologies (including TargetScan, which identifies novel antigens), that recognize diverse targets and are associated with multiple HLA types. These TCRs are used to manufacture enhanced TCR-T therapies for both hematologic and solid tumor malignancies.

The heme program is led by TSC-100 and TSC-101, which target the HA-1 and HA-2 antigens in patients with AML, MDS and ALL undergoing allogeneic hematopoietic cell transplantation, with the goal of eliminating residual disease, promoting complete donor chimerism and preventing relapse. They are being studied in the multi-arm ALLOHA Phase 1 umbrella trial, with 15 clinical sites activated, and TSC-102-A0301, targeting a CD45 epitope, has moved into IND-enabling activities. The solid tumor program is developing autologous TCR-T candidates, with seven in Phase 1 development targeting HPV16 E7, MAGE-C2, MAGE-A4, PRAME and MAGE-A1 across different HLA types.

Initial indications include non-small cell lung cancer, sarcoma, head and neck cancer, cervical cancer, and anal and genital cancer. To address tumor heterogeneity and HLA loss, the company is developing multiplex TCR-T therapy (T-Plex), which administers up to three TCR-T products selected from the ImmunoBank and customized to each patient's tumor targets and intact HLA genes. The FDA has cleared its T-Plex IND, and the PLEXI-T Phase 1 trial has 15 sites activated.

Its products are made with a non-viral transposon/transposase system (T-Integrate) in an internal GMP facility with estimated capacity for up to 250 TCR-T components per year, supplemented by a global CDMO engaged for additional clinical capacity and potential commercialization. The larger cargo capacity allows added enhancements, including CD8α/β to engineer both cytotoxic and helper T cells and, in solid tumor candidates, a dominant-negative TGFβRII to improve persistence. The company has treated over 30 patients with six TCR-T candidates.

Beyond oncology, it has a research collaboration and license agreement with Amgen to identify antigens recognized by T cells in Crohn's disease, under which it received a $30.0 million upfront payment and is eligible for over $500 million in milestones plus tiered single-digit royalties, and it intends to opportunistically pursue further partnerships in autoimmune and infectious diseases while developing next-generation allogeneic and in vivo engineering capabilities.